Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0032290 (
aspiration pneumonia
)
2,291
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Objectives:
The use of dexmedetomidine and ketamine (DEX-KET) combination for magnetic resonance imaging (MRI) sedation has not been evaluated. We investigated the efficacy and safety of DEX-
KET
for sedation of patients undergoing MRI of the brain.
Methods:
This quasi-experimental study was conducted to compare the DEX-
KET
combination and midazolam for MRI sedation. We included 72 patients undergoing brain MRI following bolus injection of midazolam or DEX-
KET
. In August 1, 2016 a new MRI sedation protocol was implemented. After protocol implementation, bolus doses of DEX-
KET
were administered (DEX-KET group). Thirty-six patients from the MIDA group and 36 patients from the DEX-
KET
group underwent MRI sequences and were compared regarding the MRI scan time and sedation-related complications (desaturation, hypotension, cardiorespiratory arrest, and
aspiration pneumonia
).
Results:
All MRI sequences were completed for 30 patients (83.3%) from the MIDA group and for 33 patients (91.7%) from the DEX-
KET
group (
P
= 0.476). The median MRI scan time was 100.0 min (interquartile range, 87.0-111.5 min) in the MIDA group and 53.5 min (interquartile range, 45.0-60.5 min) in the DEX-
KET
group (
P
< 0.001). Complications occurred in 24 (66.7%) and 8 (22.2%) patients of the MIDA and DEX-
KET
group, respectively (
P
< 0.001).
Conclusions:
The efficacy of DEX-
KET
sedation was comparable to that of midazolam for MRI examination. DEX-
KET
was related to shorter scan time and lower occurrence of complications compared to midazolam.
...
PMID:Combination of Dexmedetomidine and Ketamine for Magnetic Resonance Imaging Sedation. 3110 37